BristolMyers Squibb Company discovers develops licenses manufactures and markets biopharmaceutical products worldwide It offers products for hematology oncology cardiovascular immunology fibrotic neuroscience and covid19 diseases The companys products include Revlimid an oral immunomodulatory drug for the treatment of multiple myeloma Eliquis an oral inhibitor for reduction in risk of strokesystemic embolism in NVAF and for the treatment of DVTPE Opdivo for anticancer indications PomalystImnovid indicated for patients with multiple myeloma and Orencia for adult patients with active RA and psoriatic arthritis It also provides Sprycel for the treatment of Philadelphia chromosomepositive chronic myeloid leukemia Yervoy for the treatment of patients with unresectable or metastatic melanoma Abraxane a proteinbound chemotherapy product Reblozyl for the treatment of anemia in adult patients with beta thalassemia and Empliciti for the treatment of multiple myeloma In addition the company offers Zeposia to treat relapsing forms of multiple sclerosis Breyanzi a CD19directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large Bcell lymphoma Inrebic an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis and Onureg for the treatment of adult patients with AML It sells products to wholesalers distributors pharmacies retailers hospitals clinics and government agencies The company was formerly known as BristolMyers Company The company was founded in 1887 and is headquartered in New York New York
0.00%
Last week
1 Week Post-Dividend Price Movement
Price Movement Trend 52.4% upward movements, 3.7% stable prices after dividend payments
Warning: include(/home/individends/public_html/dividend-content.php?ajax=true&ticker=BMY): Failed to open stream: No such file or directory in /home/individends/public_html/stock.php on line 708
Warning: include(): Failed opening '/home/individends/public_html/dividend-content.php?ajax=true&ticker=BMY' for inclusion (include_path='.:/opt/cpanel/ea-php83/root/usr/share/pear') in /home/individends/public_html/stock.php on line 708
BristolMyers Squibb Company (BMY) Profile
BristolMyers Squibb Company discovers develops licenses manufactures and markets biopharmaceutical products worldwide It offers products for hematology oncology cardiovascular immunology fibrotic neuroscience and covid19 diseases The companys products include Revlimid an oral immunomodulatory drug for the treatment of multiple myeloma Eliquis an oral inhibitor for reduction in risk of strokesystemic embolism in NVAF and for the treatment of DVTPE Opdivo for anticancer indications PomalystImnovid indicated for patients with multiple myeloma and Orencia for adult patients with active RA and psoriatic arthritis It also provides Sprycel for the treatment of Philadelphia chromosomepositive chronic myeloid leukemia Yervoy for the treatment of patients with unresectable or metastatic melanoma Abraxane a proteinbound chemotherapy product Reblozyl for the treatment of anemia in adult patients with beta thalassemia and Empliciti for the treatment of multiple myeloma In addition the company offers Zeposia to treat relapsing forms of multiple sclerosis Breyanzi a CD19directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large Bcell lymphoma Inrebic an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis and Onureg for the treatment of adult patients with AML It sells products to wholesalers distributors pharmacies retailers hospitals clinics and government agencies The company was formerly known as BristolMyers Company The company was founded in 1887 and is headquartered in New York New York